Pathogenesis and management of chronic allograft nephropathy

Drugs

Volumn 68, Issue SUPPL. 1, 2008, Pages 21-31

  Yilmaz, Serdar ^a,b,c   Sar, Aylin ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Southern Alberta Transplant Program (ALTRA)   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

Calcineurin inhibitors, adverse reactions; Kidney disorders, drug induced; Sirolimus, therapeutic use

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALGORITHM; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; LONG TERM CARE; NEPHROTOXICITY; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SURVIVAL TIME;

ALGORITHMS; CALCINEURIN; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 42649096310     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868001-00004     Document Type: Review

References (56)

1. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001; 38 (6 Suppl. 6): S44-50
2. Joosten SA, van Kooten C, Sijpkens YW, et al. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int 2004; 65 (5): 1556-9
3. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81 (5): 643-54
4. Merville P. Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 2005; 65 (5): 615-31
5. Hume DM, Merrill JP, Miller BF, et al. Experience with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955 Feb; 34 (2): 327-82
6. Calne RY. The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet 1960 Feb 20; 1: 417-8
7. Porter KA, Calne RY, Zukoski CF. Vascular and other changes in 200 canine renal homotransplants treated with immunosuppressive drugs. Lab Invest 1964 Jul; 13: 810-24
8. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 Feb; 55 (2): 713-23
9. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 Mar; 7 (3): 518-26
10. Isoniemi H, Taskinen E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994 Dec 15; 58 (11): 1195-8
11. Yilmaz S, Yilmaz A, Hayry P. Chronic renal allograft rejection can be predicted by area under the serum creatinine versus time curve (AUCCr). Kidney Int. 1995 Jul; 48 (1): 251-8
12. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 Dec 11; 349 (24): 2326-33
13. Yilmaz S, McLaughlin K, Paavonen T, et al. Clinical predictors of renal allograft histopathology: a comparative study of single-lesion histology versus a composite, quantitative scoring system. Transplantation 2007 Mar 27; 83 (6): 671-6
14. Yilmaz S, Sar A, Gonul I, et al. Comparison of composite histologic scores with Banff 97 chronic /sclerosing lesion grading for prediction of progressive allograft. dysfunction/graft loss [abstract no. 134]. American Transplant Congress 2007; May 5-9; San Francisco, CA. Am J Transplant 2007 May; 7 Suppl. 2: 181
15. Yilmaz S, Sar A, Gonul I, et al. Interstitial inflammation and vascular intimal thickening predict long term graft function better than Banff 97 chronic/sclerosing lesion grading [abstract no. 133]. American Transplant Congress 2007; May 5-9; San Francisco, CA. Am J Transplant 2007 May; 7 Suppl. 2: 180
16. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005 Oct; 5 (10): 2464-72
17. Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007 Feb; 7 (2): 356-65
18. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002 Jul; 62 (1): 311-8
19. Salvadori M, Rosati A, Bock A, et al. One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST Observational Study. Transplant Proc 2003 Dec; 35 (8): 2863-7
20. Siddiqi N, McBride MA, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004 May; 65 (5): 1906-13
21. Salvadori M, Rosati A, Bock A, et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation 2006 Jan 27; 81 (2): 202-6
22. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003 Dec; 3 (12): 1560-5
23. Yilmaz S, Isik I, Afrouzian M, et al. Evaluating the accuracy of functional biomarkers for detecting histological changes in chronic allograft nephropathy. Transpl Int 2007 Jul; 20 (7): 608-15
24. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III: how to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994 Mar 2; 271 (9): 703-7
25. Morozumi K, Thiel G, Gudat F, et al. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in patients with renal allografts. Transplant Proc 1993 Feb; 25 (1 Pt 1): 537-9
26. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988 Jun; 20 3 Suppl. 3: 759-71
27. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000 Jun 27; 69 (12 Suppl.): SS11-3
28. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004 Aug 27; 78 (4): 557-65
29. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005 Jul; 5 (7): 1748-56
30. Gonwa TA, Hricik DE, Brinker K, et al. Sirolimus Renal Function Study Group: improved renal function in sirolimus treated renal transplant patients after early cyclosporin elimination. Transplantation 2002; 74: 1560-7
31. Baboolal K. A phase III prospective randomized study to evaluate concentration controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404-8
32. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporin withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-86
33. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves one year kidney graft structure and function in sirolimus treated patients. Transplantation 2003; 75: 998-1003
34. Jardine AG. Phase III prospective randomized study to evaluate the safety and efficacy of concentration controlled Rapamune (sirolimus) with cyclosporine dose minimisation or elimination in de novo renal allograft recipients at 12 months [abstract]. Am J Transplant 2004; 4 Suppl. 8: 286
35. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308-14
36. Mota A, Arias M, Taskinen EI, et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004 Jun; 4 (6): 953-61
37. Oberbauer R, Segoloni G, Campistol JM, et al. Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005 Jan; 18 (1): 22-8
38. Nankivell BJ, Gruenewald SM, Allen RD, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995 Jun 27; 59 (12): 1683-9
39. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006 Jan; 6 (1): 100-8
40. Russ G, Segoloni G, Oberbauer R, et al., on behalf of the Rapamune Maintenance Regimen Study Group. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005 Nov 15; 80 (9): 1204-11
41. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006 Nov 15; 82 (9): 1153-62
42. Schena FP, Vitko S, Wali R, et al., on behalf of the Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18-month results from a randomized, open-label comparative trial [abstract no. 1026]. Program and abstracts of the World Transplant Congress; 2006 Jul 22-27; Boston (MA)
43. Patel A, Weir M, Wali R, et al. Spare-the-Nephron (STN) Trial: updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients. [abstract no. 1138]. Program and abstracts of the American Transplant Congress; 2007 May 5-9; San Francisco (CA)
44. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 Mar; 6 (3): 514-22
45. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005 Oct; 5 (10): 2531-8
46. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002 Oct; 74 (8): 1070-6
47. Flechner S, Glyda M, Steinberg S, Harler MB, for the ORION Trial Investigators Transplant Center. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study [abstract no. 1141]. American Transplant Congress; 2007 May 5-9; San Francisco (CA)
48. Flechner S, Glyda M, Steinberg S, Harler MB, for the ORION trial investigators transplant center. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study [abstract no. 52]. American Transplant Congress; 2007 May 5-9; San Francisco (CA)
49. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004 Nov; 4 (11): 1776-85
50. Ekberg H, Tedesco-Silva H, Demirbas A, et al. SYMPHONY - comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no. 49]. Program and abstracts of the World Transplant Congress; 2006 Jul 22-27; Boston (MA)
51. Yilmaz S, Tomlanovich S, Mathew T, et al. Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003 Mar; 14 (3): 773-9
52. Goldberg BB, Pollack HM, Kellerman E. Ultrasonic localization for renal biopsy. Radiology 1975; 115: 167-70
53. Wiseman DA, Hawkins R, Numerow LM, et al. Percutaneous renal biopsy utilizing real time, ultrasonic guidance and a semiautomated biopsy device. Kidney Int 1990; 38: 347-9
54. Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 2003; 76: 969-73
55. Hergesell O, Felten H, Andrassy K, et al. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant 1998; 13: 975-7
56. Schwarz A, Gwinner W, Hiss M, et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5: 1992-6